MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[31] Optimization of biologics to reduce treatment failure in inflammatory bowel diseases
Bourchany, Aurelie
De Saint-Joseph, Cyrielle Gilletta
Breton, Anne
Barreau, Frederick
Mas, Emmanuel
CURRENT OPINION IN PHARMACOLOGY, 2020, 54 : 51 - 58
[32] Chronic inflammatory bowel diseases: state of the art
Maul, J.
Siegmund, B.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (36) : 1771 - 1775
[33] New molecules in the treatment of inflammatory bowel disease
Chaparro, Maria
Gisbert, Javier P.
GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (06): : 411 - 423
[34] CYCLOSPORINE-A TREATMENT IN INFLAMMATORY BOWEL DISEASES
BRAZIER, F
FINET, L
DUCHMANN, JC
DUPAS, JL
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1995, 19 (05): : 494 - 504
[35] The role of hypnotherapy for the treatment of inflammatory bowel diseases
Moser, Gabriele
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (06) : 601 - 606
[36] Surgical treatment of severe inflammatory bowel diseases
Leowardi, C
Heuschen, G
Kienle, P
Heuschen, U
Schmidt, J
DIGESTIVE DISEASES, 2003, 21 (01) : 54 - 62
[37] Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease
Siegmund, Britta
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S761 - S766
[38] Azathioprine in the treatment of chronic inflammatory bowel diseases
Herrlinger, K
Stange, EF
MEDIZINISCHE KLINIK, 2000, 95 (04) : 201 - 206
[39] Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases
Herfarth, Hans H.
Kappelman, Michael D.
Long, Millie D.
Isaacs, Kim L.
INFLAMMATORY BOWEL DISEASES, 2016, 22 (01) : 224 - 233
[40] Surgical treatment of inflammatory bowel diseases and pregnancy
Ilnyckyj, Alexandra
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2007, 21 (05) : 819 - 834

← 1 2 3 4 5 →